Logo image
Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis
Journal article   Open access   Peer reviewed

Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis

Lauren Clevenger, Andrew Schrepf, Koenraad Degeest, David Bender, Michael Goodheart, Amina Ahmed, Laila Dahmoush, Frank Penedo, Joseph A Lucci III, Premal H Thaker, …
Cancer, Vol.119(17), pp.3234-3241
09/01/2013
DOI: 10.1002/cncr.28188
PMCID: PMC3775963
PMID: 23797955
url
https://doi.org/10.1002/cncr.28188View
Published (Version of record) Open Access

Abstract

Sleep disturbance is a common clinical complaint of oncology patients and contributes to substantial morbidity. However, because most sleep studies have been cross-sectional, associations between sleep quality and distress in patients with ovarian cancer over time remain unclear. This prospective longitudinal study examined rates of sleep disturbance; contributions of depression, anxiety, and medication use in sleep disturbance; and associations between sleep quality and quality of life (QOL) during the first year after diagnosis among women with ovarian cancer. Women with a pelvic mass completed measures of sleep quality, depression, anxiety, and QOL before surgery. Those diagnosed with primary epithelial ovarian, fallopian tube, or peritoneal cancer repeated surveys at 6 months and 1 year after diagnosis. Mixed modeling was used to examine trajectories of psychosocial measures over time, as well as associations between changes in distress and sleep quality. Relationships between changes in sleep and QOL were also examined. The majority of patients reported disturbed global sleep (Pittsburgh Sleep Quality Index > 5) at all 3 time points. Medications for sleep and pain were associated with worse sleep at all time points. Greater increases in depression were associated with increased disturbances in sleep quality over time (P < .04). Worsening sleep was also associated with declines in QOL over time (P < .001). Sleep disturbance is common and persistent in women with ovarian cancer, and is linked to depressive symptoms and QOL. Pharmacologic treatment does not appear to adequately address this problem. Results highlight the need for ongoing screening and intervention for sleep disturbance in this population.
Quality of Life Anti-Anxiety Agents - administration & dosage United States - epidemiology Prospective Studies Sleep Wake Disorders - drug therapy Humans Middle Aged Hypnotics and Sedatives - administration & dosage Ovarian Neoplasms - pathology Anxiety - drug therapy Peritoneal Neoplasms - diagnosis Ovarian Neoplasms - ethnology Depression - etiology Depression - drug therapy Neoplasm Grading Sleep Wake Disorders - epidemiology Neoplasms, Glandular and Epithelial - psychology Stress, Psychological - epidemiology Anxiety - epidemiology Adult Female Neoplasms, Glandular and Epithelial - diagnosis Peritoneal Neoplasms - psychology Sleep Wake Disorders - etiology Ovarian Neoplasms - psychology Depression - epidemiology Ovarian Neoplasms - diagnosis Stress, Psychological - drug therapy Analgesics - administration & dosage Carcinoma, Ovarian Epithelial Antidepressive Agents - administration & dosage Aged Neoplasm Staging Longitudinal Studies Anxiety - etiology Stress, Psychological - etiology

Details

Metrics

Logo image